** Drug developer Jasper Therapeutics' JSPR.O shares fall 70.7% to $1.98 premarket
** Company says its experimental drug, briquilimab, achieved a complete response at week 12 in an early-stage study to treat a skin condition called chronic spontaneous urticaria (CSU)
** But the results were affected by an issue with one specific drug product lot
** CSU causes red, itchy bumps on the skin that come and go without a clear reason
** Company says it halted the drug's asthma trial due to the same drug product lot issue
** In the 10 patients with CSU who received the problematic drug product lot, reduction in mean tryptase levels, a marker of mast cell activity, was lower than expected and there was no noticeable improvement, company says
** Jasper is investigating the issue and expects results in the coming weeks
** As of last close, stock down 68.33% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.